[9] T. Karantanos, C.P. Evans, B. Tombal, T.C. Thompson, R. Montironi, W.B. Isaacs, Understanding
the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level,
European urology, 67 (2015) 470-479.
[10] J. Luo, G. Attard, S.P. Balk, C. Bevan, K. Burnstein, L. Cato, A. Cherkasov, J.S. De Bono, Y.
Dong, A.C. Gao, M. Gleave, H. Heemers, M. Kanayama, R. Kittler, J.M. Lang, R.J. Lee, C.J.
Logothetis, R. Matusik, S. Plymate, C.L. Sawyers, L.A. Selth, H. Soule, W. Tilley, N.L. Weigel, A.
Zoubeidi, S.M. Dehm, G.V. Raj, Role of Androgen Receptor Variants in Prostate Cancer: Report from
the 2017 Mission Androgen Receptor Variants Meeting, European urology, 73 (2018) 715-723.
[11] Vivek K. Arora, Schenkein E , Murali R , et al. Glucocorticoid Receptor Confers Resistance to
Antiandrogens by Bypassing Androgen Receptor Blockade[J]. Cell, 2013, 155(6):1309-1322.
[12] C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, C.L.
Sawyers, Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, 172 (2004)
2113-2113.
[13] M. Grossmann, A.S. Cheung, J.D. Zajac, Androgens and prostate cancer; pathogenesis and
deprivation therapy, Best Practice & Research Clinical Endocrinology & Metabolism, 27 (2013) 603-
616.
[14] F. Labrie, A. Dupont, A. Bellanger, New approach in the treatment of prostate cancer: Complete
instead of partial withdrawal of androgen. Prostate.4 (1983) 579-584.
[15] E.D. Crawford, M.A. Eisenberger, D.G. McLeod, J.T. Spaulding, R. Benson, F.A. Dorr, B.A.
Blumenstein, M.A. Davis, P.J. Goodman, A controlled trial of leuprolide with and without flutamide in
prostatic carcinoma. N Engl J Med. 321 (1989) 419-424.
[16] B.E. Gryder, M.J. Akbashev, M.K. Rood, E.D. Raftery, W.M. Meyers, P. Dillard, S. Khan, A.K.
Oyelere, Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase
Inhibitors, Acs Chemical Biology, 8 (2013) 2550-2560.
[17] K.S. Wang, H.L. Ruan, T.B. Xu, L. Liu, D. Liu, H.M. Yang, X.P. Zhang, K. Chen, Recent
advances on the progressive mechanism and therapy in castration-resistant prostate cancer, Onco
Targets Ther. 11 (2018) 3167-3178.
[18] T.S. Vasaitis, R.D. Bruno, V.C. Njar, CYP17 inhibitors for prostate cancer therapy, Journal of
Steroid Biochemistry & Molecular Biology, 125 (2011) 23-31.
[19] C.P. Owen, 17α-hydroxylase/17,20-lyase (P45017α) inhibitors in the treatment of prostate cancer:
A review, Anti-cancer agents in medicinal chemistry, 9 (2009) 613-626.
[20] M. Akhtar, J.N. Wright, P. Lee-Robichaud, A review of mechanistic studies on aromatase (CYP19)
and 17α-hydroxylase-17,20-lyase (CYP17), Journal of Steroid Biochemistry & Molecular Biology, 125
(2011) 2-12.
[21] N. Bruchovsky, J.D. Wilson, The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-
one by rat prostate in vivo and in vitro, Journal of Biological Chemistry, 243 (1968) 2012.
[22] A. Bryce, C.J. Ryan, Development and clinical utility of abiraterone acetate as an androgen
synthesis inhibitor, Clin Pharmacol Ther. 91(2012) 101-108.
[23] V.C.O. Njar, A.M.H. Brodie, Discovery and Development of Galeterone (TOK-001 or VN/124-1)
for the Treatment of All Stages of Prostate Cancer, Journal of Medicinal Chemistry, 58 (2015) 2077-
2087.
[24] L. Yin, Q. Hu, CYP17 inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents,
Nat Rev Urol. 11 (2014) 32-42.
[25] Y. Chen, N.J. Clegga, H.I. Scherb, Antiandrogens and androgen depleting therapies in prostate
cancer: novel agents for an established target, Lancet Oncol. 10(2009) 981-991.
[26] A. Anighoro, J. Bajorath, G. Rastelli, Polypharmacology: challenges and opportunities in drug
discovery. J. Med. Chem. 57 (2014) 7874-7887.
[27] J.U. Peters, Polypharmacology - foe or friend? J. Med. Chem. 56 (2013) 8955-8971.
[28] G.S. Luo, Z.P. Tang, K.J. Lao, X.Y. Li, Q.D. You, H. Xiang, Structure-activity relationships of
2,4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity, Eur. J.
Med. Chem., 150 (2018) 783-795.
[29] KJ. Lao, J. Sun, C. Wang, Y. Wang, Q, You, H. Xiao, H. Xiang, Design, synthesis and biological
evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and
androgen receptor antagonists, 27 (2017) 4212-4217.
[30] G.S. Luo, X.Y. Li, G.Q. Zhang, C.Z. Wu, Z.P. Tang, L.Y. Liu, Q.D. You, H. Xiang, Novel
SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - a possible way to dual
ERalpha/VEGFR-2 ligands for treatment of breast cancer, Eur. J. Med. Chem., 140 (2017) 252-273.
[31] K.J. Lao, J.S. C. Wang, W.T. Lyu, B.S. Zhou, R.H. Zhao, Q. Xu, Q.D. You, H. Xiang, Design,
synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as
inhibitors of 5α-reductase type 1 and 2, steroids, 124 (2017) 29-34.